Robert Flaumenhaft, MD, PhD
Professor of Medicine
Harvard Medical School
Division of Hemostasis and Thrombosis
Beth Israel Deaconess Medical Center
3 Blackfan Circle, Room 905, Boston MA 02215
Tel: 617-735-4005 FAX: 617 735-4000
Dr. Flaumenhaft received his M.D. and Ph.D. from NYU School of Medicine, completed a fellowship in Hematology/Oncology at Beth Israel Deaconess Medical Center (BIDMC), and received a M.M.Sc. from Harvard Medical School. He is currently a Professor at Harvard Medical School and Chief of the Division of Hemostasis and Thrombosis at BIDMC. His laboratory focuses on platelet and endothelial biology and mechanisms of thrombus formation. He also cares for patients with bleeding or clotting disorders. Dr. Flaumenhaft is Director of the T32 training program entitled, “Program in Blood Coagulation and Vascular Biology”. He also is Director of the BIDMC Organ-on-Chip Facility. He has previously served on or currently serves on several editorial boards in the field of Hemostasis and Thrombosis including Blood, JCI Insight, JTH, Thrombosis and Haemostasis , Thrombosis Research, and Seminars in Thrombosis and Hemostasis. He was Chairman of the Hemostasis and Thrombosis NIH Study Section, scientific co-chair of the ASH annual meeting and Chairman of the FASEB meeting on Functional Disulfide Bonds in Health and Disease. His work in in the field of Hemostasis and Thrombosis has earned him a Junior Faculty Award from the American Society of Hematology, a Career Award from the Burroughs Wellcome Fund, an Established Investigator Award from the American Heart Association, and an Outstanding Investigator Award from NIH. He was elected to the American Society for Clinical Investigation and to the Association of American Physicians. Dr. Flaumenhaft is also the founder of PlateletDiagnostics, a device company that specializes in the development of platelet function tests.
Current and Recent Grants
1R35HL135775-01 (PI, Flaumenhaft)
Thiol Isomerases in Hemostasis and Thrombosis
The goal of this project is to evaluate the role of thiol isomerases in hemostasis and thrombosis in health and disease. The studies will include in vitro studies, animal models of thrombotic disease, and human studies all focused around the common goal of understanding how thiol isomerase contribution to bleeding and clotting.
5R01HL125275-03 (PI, Flaumenhaft)
Targeting endothelium in sepsis
This project will study protective signaling mechanisms in sepsis and evaluate the efficacy of activating cytoprotective signaling in the setting of sepsis. The mechanisms underlying thrombosis of sepsis will be studied. In addition, an endothelial barrier function assay will be used as a new method to monitor progression and direct therapy in sepsis.
5T32HL007917-18 (PI, Flaumenhaft)
Program in Blood Coagulation and Vascular Biology
This is a training grant. Learn more.
4U54HL112302-05 (Leader, Project 2)
Protein disulfide isomerases: A new class of antithrombotic targets
High throughput screening to identify potent and selective inhibitors of PDI are performed.
5R01GM115417-02 (subcontract; PI, Whitman)
NIH/NIGMS/Harvard Medical School
The first secreted Tyrosine kinase
The goal of this subcontract is to support studies that will evaluate the role of platelet VLK thrombus formation in vivo.